Skip to main content

Advertisement

SpringerLink
Log in

Factors Influencing Non-albicans Candidemia: A Case–Case–Control Study

  • Published:
Mycopathologia Aims and scope Submit manuscript

Abstract

The study identified factors predisposing to non-albicans candidemia with special interest to prior antimicrobial treatment. A retrospective, case–case–control study was performed at the University Hospital of Heraklion, Greece, from November 2007 through September 2011 including adult patients. The study had three groups. The first included 58 patients with non-albicans candidemia, the second 48 with C. albicans candidemia, while the third (control) 104 without candidemia. Each of the two candidemia groups was compared with the control using multivariate logistic regression model. The mean (SD) age of the non-albicans, the albicans and the control patients was 67 (12), 67 (18) and 59 (19) years, respectively. The most common non-albicans Candida spp. isolated were C. parapsilosis in 19 patients (33%), C. glabrata in 17 (29%) and C. tropicalis in 15 (26%). Independent risk factors for non-albicans candidemia were prior treatment with quinolones (p < 0.001), b-lactam-b-lactamase inhibitors (p = 0.011) and presence of central venous catheter (p = 0.05), while for C. albicans candidemia were prior treatment with quinolones (p < 0.001), carbapenems (p = 0.003) along with cardiac disease (p < 0.001). Neither duration of hospitalization nor in-hospital mortality [41% for the non-albicans vs 29% for C. albicans group (p = 0.192)] was significantly different between the two candidemia groups. The study reveals the role of antimicrobial exposure as a risk factor for candidemia caused by different species. Prior treatment with b-lactam-b-lactamase inhibitors was associated with non-albicans, while with carbapenems with C. albicans candidemia. Prior use of quinolones was associated with candidemia in general.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wisplinhoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17.

    Article  Google Scholar 

  2. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232–9.

    Article  PubMed  Google Scholar 

  3. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992;15:414–21.

    Article  CAS  PubMed  Google Scholar 

  4. Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med. 1995;155:2429–35.

    Article  CAS  PubMed  Google Scholar 

  5. Nucci M, Colombo AL, Silveira F, et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol. 1998;19:846–50.

    Article  CAS  PubMed  Google Scholar 

  6. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and invitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 2004;42:1519–27.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect. 2002;50:56–65.

    Article  CAS  PubMed  Google Scholar 

  8. Yamamura DL, Rotstein C, Nicole LE, Ioannou S. Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992–1994. Fungal Disease Registry of the Canadian Infectious Disease Society. Canadian Med Assoc J. 1999;160:493–9.

    CAS  Google Scholar 

  9. Viscoli C, Girmenia Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28:1071–9.

    Article  CAS  PubMed  Google Scholar 

  10. Colombo AL, Nucci M, Salomao R, et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis. 1999;34:281–6.

    Article  CAS  PubMed  Google Scholar 

  11. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect. 2004;10(Suppl 1):11–23.

    Article  CAS  PubMed  Google Scholar 

  12. Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother. 1998;42:2645–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis. 2006;42:244–51.

    Article  CAS  PubMed  Google Scholar 

  14. Ben-Ami R, Olshtain-Pops K, Krieger M, Israeli Candidemia Study Group, et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother. 2012;56:2518–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chi HW, Yang YS, Shang ST, et al. Candida albicans versus non-albicans bloodstream infections: the comparison of risk factors and outcome. J Microbiol Immunol Infect. 2011;44:369–75.

    Article  CAS  PubMed  Google Scholar 

  16. Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother. 2010;54:3149–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Rodríguez D, Almirante B, Cuenca-Estrella M, Rodríguez-Tudela JL, Mensa J, Ayats J, Sanchez F, Pahissa A, Barcelona Candidemia Project Study Group. Predictors of candidaemia caused by non-albicans Candida species: results of a population-based surveillance in Barcelona, Spain. Clin Microbiol Infect. 2010;16:1676–82.

    Article  PubMed  Google Scholar 

  18. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in non neutropenic patients. Ann Pharmacother. 2007;41:568–73.

    Article  PubMed  Google Scholar 

  19. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case–case–control study. Antimicrob Agents Chemother. 2005;49:4555–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Yapar N, Pullukcu H, Avkan-Oguz V, et al. Evaluation of species distribution and risk factors of candidemia: a multicenter case–control study. Med Mycol. 2011;49:26–31.

    Article  PubMed  Google Scholar 

  21. Kaye KS, Harris AD, Samore M, Carmeli Y. The case–case–control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol. 2005;26:346–51.

    Article  PubMed  Google Scholar 

  22. Samonis G, Gikas A, Anaissie EJ, et al. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother. 1993;37:51–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Pultz NJ, Stiefel U, Ghannoum M, Helfand MS, Donskey CJ. Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob Agents Chemother. 2005;49:438–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis. 1996;22(Suppl 2):S73–88.

    Article  PubMed  Google Scholar 

  25. Samonis G, Maraki S, Leventakos K, et al. Comparative effects of ertapenem, imipenem, and meropenem on the colonization of the gastrointestinal tract of mice by Candida albicans. Med Mycol. 2006;44:233–5.

    Article  CAS  PubMed  Google Scholar 

  26. Maraki S, Lionakis S, Ntaoukakis M, et al. Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans. Med Mycol. 2011;49:419–23.

    Article  CAS  PubMed  Google Scholar 

  27. Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008;46:1206–13.

    Article  PubMed  Google Scholar 

  28. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg. 2008;106:523–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Presented in part at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 9–12, 2012; San Francisco, California.

Funding

This study has been supported by the Hellenic Society for Medical Mycology (Grant number 557A / 07-04-2014).

Author information

Authors and Affiliations

  1. Infectious Disease Unit, Department of Internal Medicine, University Hospital of Heraklion, 71 110, Heraklion, Crete, Greece

    Diamantis P. Kofteridis, Dimitra Dimopoulou, Angeliki M. Andrianaki, Nikolaos A. Spernovasilis & George Samonis

  2. Clinical Microbiology, University Hospital of Heraklion, 71110, Heraklion, Crete, Greece

    Athanasia Christidou & Sofia Maraki

  3. Department of Oncology, Mälarsjukhuset, Eskilstuna, Sweden

    Antonis Valachis

  4. University of Uppsala, Uppsala, Sweden

    Antonis Valachis

Authors
  1. Diamantis P. Kofteridis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonis Valachis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimitra Dimopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angeliki M. Andrianaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Athanasia Christidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sofia Maraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nikolaos A. Spernovasilis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. George Samonis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diamantis P. Kofteridis.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kofteridis, D.P., Valachis, A., Dimopoulou, D. et al. Factors Influencing Non-albicans Candidemia: A Case–Case–Control Study. Mycopathologia 182, 665–672 (2017). https://doi.org/10.1007/s11046-017-0146-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11046-017-0146-4

Keywords

Search

Navigation